Coronary Stents Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

The Coronary Stents Market Report is Segmented by Product Type (Drug Eluting Stent, Bare Metal Coronary Stent, and More), Biomaterial (Metallic, Polymeric and More), Mode of Delivery (Balloon-Expandable Stent and Self-Expanding Stent), End User (Hospitals, Ambulatory Surgical Centers and More), and Geography (North America, Europe, Asia-Pacific, and More). The Market Forecasts are Provided in Terms of Value (USD).

Coronary Stent Market Size and Share

Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Compare market size and growth of Coronary Stent Market with other markets in Healthcare Industry

Coronary Stent Market Analysis by Mordor Intelligence

The coronary stents market is valued at USD 8.29 billion in 2025 and is projected to reach USD 10.43 billion by 2030, advancing at a 4.69% CAGR during the forecast period. Healthy expansion is supported by steady procedure volumes, a shift toward value-based care, and rapid integration of AI-guided imaging that improves precision and reduces complications. Hospitals continue favoring drug-eluting platforms with ultrathin struts that shorten dual antiplatelet therapy, while public procurement reforms in Asia alter global pricing dynamics. Supply-chain constraints for cobalt-chromium alloys place a ceiling on high-end production, yet material innovation is narrowing that gap. Consolidation among diversified med-tech firms signals a maturing field where adjacent technologies such as intravascular lithotripsy augment core stent portfolios.

Key Report Takeaways

  • By product type, drug-eluting stents held 76.23% of the coronary stents market share in 2024, while bioabsorbable vascular scaffolds are forecast to expand at a 7.66% CAGR to 2030.
  • By biomaterial, metallic platforms accounted for 67.66% of the coronary stents market size in 2024; polymeric scaffolds are projected to grow at an 8.08% CAGR through 2030.
  • By mode of delivery, balloon-expandable systems commanded 80.12% revenue share in 2024; self-expanding systems exhibit the fastest CAGR of 6.57% to 2030.
  • By end user, hospitals represented 58.92% of procedures in 2024, whereas ambulatory surgical centers are expected to post a 6.84% CAGR over the same horizon.
  • By geography, North America led with 35.24% revenue share in 2024; Asia-Pacific is advancing at a 7.46% CAGR through 2030.

Segment Analysis

By Product Type: DES Dominance Faces BVS Innovation

Drug-eluting stents generated 76.23% of revenue in 2024, establishing the largest share of the coronary stents market. The segment benefits from a continuous flow of data supporting low restenosis and thrombosis rates with ever thinner struts. Competition now focuses on polymer chemistry, drug kinetics, and radial strength, areas that expand margins even under price pressure. Bioabsorbable vascular scaffolds, while only a fraction of sales today, record a 7.66% CAGR through 2030 as safety profiles improve. Recent trials like INFINITY-SWEDEHEART that showed 0.6% target-vessel failure for DynamX bioadaptor validate renewed clinical confidence.

Next-generation BVS seek to merge temporary scaffolding with the radial performance of metals. Regulatory acceptance widens indications beyond coronary arteries into peripheral territories, such as Abbott’s Esprit BTK receiving FDA nod for below-the-knee lesions. This broadens platform potential, spurring incremental R&D. Meanwhile, bare-metal stents retain utility in scenarios needing short antiplatelet regimens, and dual-therapy stents address high bleeding-risk patients. The varied lineup allows physicians to tailor therapy rather than apply a one-size-fits-all approach.

Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Note: Segment shares of all individual segments available upon report purchase

By Biomaterial: Metallic Platforms Drive Polymer Innovation

Metallic designs controlled 67.66% of sales in 2024, reflecting physician preference for cobalt-chromium and platinum-chromium alloys that deliver strong radial support. Advances in metallurgy enable 60-micrometer struts without compromising fatigue resistance, meeting demand for high deliverability. Polymeric scaffolds, though smaller today, are gaining at an 8.08% CAGR as biocompatible materials alleviate chronic inflammation. Boston Scientific’s SYNERGY bioabsorbable-polymer DES demonstrated low thrombosis in a pooled cohort of 18,000 patients, bolstering payer confidence. 

Research into recombinant collagen type III coatings shows promise in eliminating drug dependence while fostering endothelial healing.[3]Nature Communications, “Drug-Free Cardiovascular Stent Functionalized With RH-Collagen III,” nature.com These innovations align with sustainability mandates and patient preference for reduced permanent implants. Manufacturers also explore hybrid constructs, pairing metallic frameworks with resorbable outer layers, to capture the best of both worlds. The biomaterial shift keeps the coronary stents market competitive for suppliers that can blend mechanical robustness with biological harmony.

By Mode of Delivery: Balloon-Expandable Systems Lead Innovation

Balloon-expandable models captured 80.12% of the coronary stents market in 2024 thanks to versatility across vessel sizes and physician familiarity. Medtronic’s Resolute Onyx showcases a single-wire design that improves radiopacity and supports one-month dual antiplatelet therapy for high bleeding-risk cohorts. These refinements sustain relevance despite maturity. Self-expanding devices, advancing at 6.57% CAGR, win favor in large proximal vessels and bifurcations where vessel diameter variability challenges fixed-size balloons. Their nitinol frameworks endow conformability that protects against malapposition.

Technological convergence is evident as manufacturers combine balloon-assisted self-expansion for precise initial placement and adaptive sizing. AI-guided deployment tools improve accuracy for both modes. Procedural planning software simulates expansion profiles, guiding device selection. Such integrations push the delivery-mode conversation beyond hardware specs into ecosystem capabilities.

Market Segment share
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Note: Segment shares of all individual segments available upon report purchase

By End User: Hospitals Adapt to Outpatient Trends

Hospitals carried 58.92% of 2024 procedure volumes but are transitioning toward complex interventions that demand hybrid operating theaters, intracoronary imaging, and surgical backup. Routine stable cases increasingly migrate to ambulatory surgical centers, which are forecast to grow at 6.84% CAGR. These centers benefit from radial access and rapid discharge protocols, aligning with payer cost containment. Cardiac catheterization laboratories operate as high-throughput hubs within integrated networks, balancing inpatient acuity with outpatient efficiency.

Same-day discharge feasibility at 78% for elective PCI underscores shifting patient pathways. Facility design now incorporates patient education zones and remote monitoring integration to support early release. End-user diversification influences procurement preferences: hospitals value multifunctional systems, while ambulatory centers focus on low inventory costs and quick case turnover. Vendors segment offerings accordingly, reinforcing downstream differentiation within the coronary stents market.

Geography Analysis

North America retained 35.24% of global revenue in 2024, underpinned by early adoption of AI-guided imaging and favorable reimbursement for high-performance DES. Hospitals leverage comprehensive insurance coverage to select premium platforms, and regulatory pathways remain predictable. Supply-chain instability tied to cobalt-chromium is partly offset by domestic alloys and streamlined FDA emergency pathways that prioritize critical cardiovascular devices. Clinical trial density further entrenches regional leadership.

Asia-Pacific is the fastest riser with a 7.46% CAGR through 2030, fueled by public procurement that widens access while compressing prices. China’s monopsony purchasing model, combined with industrial policy, accelerates domestic champion emergence. India mirrors this trajectory through price ceilings that catapult local firms past 60% share. Urbanization and rising incomes expand PCI eligibility, while public insurance schemes close affordability gaps. These factors create a volume-driven growth pattern distinct from the value-centric North American model.

Europe shows measured expansion as Medical Device Regulation harmonizes quality standards and environmental considerations shape tender scores. Brexit disruptions are settling as mutual recognition agreements stabilize cross-border supply. Sustainability criteria encourage polymers with lower life-cycle impact, nudging R&D toward degradable constructs. Meanwhile, shared-decision frameworks influenced by ISCHEMIA temper elective PCI volumes but elevate demand for best-in-class devices when intervention proceeds.

GEOGRAPHY
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Competitive Landscape

Top Companies in Coronary Stent Market

The coronary stents market is moderately consolidated. Their extensive patent estates and long-term outcome data create high switching barriers. Nonetheless, national tenders in Asia reward local sourcing, enabling companies such as Sahajanand Medical Technologies in India and Lepu Medical in China to erode incumbents’ price segments. These challengers scale rapidly, aided by state incentives and centralized procurement.

Strategic M&A activity between 2024 and 2025 illustrates convergence around complementary technologies. Johnson & Johnson’s USD 12.5 billion takeover of Shockwave Medical integrates intravascular lithotripsy that fractures calcified plaques before stent placement, enhancing outcomes in complex lesions. Teleflex’s USD 791 million purchase of Biotronik’s vascular intervention unit brings drug-coated balloons and resorbable magnesium scaffolds under one roof, creating end-to-end coronary portfolios. Players also seek digital edges, partnering with AI firms that provide imaging analytics and decision support.

Competitive pressure intensifies from supply-chain volatility. Firms with secured cobalt-chromium contracts or alternative alloy R&D avoid bottlenecks that delay rivals. Simultaneously, hospital networks weigh vendor consolidation to negotiate bulk discounts, favoring companies that bundle stents with guidewires, balloons, and imaging consoles. Such dynamics keep pricing fluid while sustaining innovation incentives.

Coronary Stent Industry Leaders

  1. Boston Scientific Corporation

  2. Medtronic Plc

  3. Abbott

  4. Terumo

  5. B. Braun SE

  6. *Disclaimer: Major Players sorted in no particular order
cornoonary
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.
Need More Details on Market Players and Competitors?
Download PDF

Recent Industry Developments

  • February 2025: Teleflex finalized its USD 791 million acquisition of Biotronik’s vascular intervention unit, adding drug-coated balloons and sirolimus-eluting resorbable magnesium scaffolds.
  • September 2024: FDA approved the Minima Stent System for pediatric coarctation of the aorta and pulmonary artery stenosis, extending cobalt-chromium frameworks to younger cohorts.
  • August 2024: INFINITY-SWEDEHEART reported DynamX bioadaptor’s 0.6% target-vessel failure at one year versus 1.8% for Resolute Onyx.

Table of Contents for Coronary Stent Industry Report

1. Introduction

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2. Research Methodology

3. Executive Summary

4. Market Landscape

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rising Prevalence CAD and Aging Population
    • 4.2.2 Shift Toward Early PCI In Acute Coronary Syndrome Guidelines
    • 4.2.3 Rapid Uptake Of Ultrathin-Strut & Biodegradable-Polymer DES
    • 4.2.4 Integration Of AI-Guided Imaging & Sizing Tools
    • 4.2.5 Hospital Preference For Day-Care Radial PCI Programs
    • 4.2.6 Government Tenders Favoring Domestic DES and Innovation Incentives
  • 4.3 Market Restraints
    • 4.3.1 Price Caps & Centralized Procurement Squeezing ASPs
    • 4.3.2 Safety Signals Around Late Scaffold Thrombosis In BVS
    • 4.3.3 Supply-Chain Shortages Of High-Purity Co-Cr Alloy
    • 4.3.4 Clinical Pushback On Routine Stenting Post-ISCHEMIA Trial
  • 4.4 Value / Supply-Chain Analysis
  • 4.5 Regulatory Landscape
  • 4.6 Technology Outlook
  • 4.7 Porter’s Five Forces Analysis
    • 4.7.1 Bargaining Power of Suppliers
    • 4.7.2 Bargaining Power of Buyers
    • 4.7.3 Threat of New Entrants
    • 4.7.4 Threat of Substitutes
    • 4.7.5 Intensity of Competitive Rivalry

5. Market Size and Growth Forecasts (Value-USD)

  • 5.1 By Product Type
    • 5.1.1 Drug-Eluting Stent (DES)
    • 5.1.2 Bare-Metal Stent (BMS)
    • 5.1.3 Bioabsorbable Vascular Scaffold (BVS)
    • 5.1.4 Dual-Therapy Stent (DTS)
  • 5.2 By Biomaterial
    • 5.2.1 Metallic
    • 5.2.2 Polymeric
    • 5.2.3 Natural / Bio-derived
  • 5.3 By Mode of Delivery
    • 5.3.1 Balloon-Expandable Stent
    • 5.3.2 Self-Expanding Stent
  • 5.4 By End User
    • 5.4.1 Hospitals
    • 5.4.2 Cardiac Catheterization Labs
    • 5.4.3 Ambulatory Surgical Centers
  • 5.5 By Geography
    • 5.5.1 North America
    • 5.5.1.1 United States
    • 5.5.1.2 Canada
    • 5.5.1.3 Mexico
    • 5.5.2 Europe
    • 5.5.2.1 Germany
    • 5.5.2.2 United Kingdom
    • 5.5.2.3 France
    • 5.5.2.4 Italy
    • 5.5.2.5 Spain
    • 5.5.2.6 Rest of Europe
    • 5.5.3 Asia-Pacific
    • 5.5.3.1 China
    • 5.5.3.2 Japan
    • 5.5.3.3 India
    • 5.5.3.4 Australia
    • 5.5.3.5 South Korea
    • 5.5.3.6 Rest of Asia-Pacific
    • 5.5.4 Middle East and Africa
    • 5.5.4.1 GCC
    • 5.5.4.2 South Africa
    • 5.5.4.3 Rest of Middle East and Africa
    • 5.5.5 South America
    • 5.5.5.1 Brazil
    • 5.5.5.2 Argentina
    • 5.5.5.3 Rest of South America

6. Competitive Landscape

  • 6.1 Market Concentration
  • 6.2 Market Share Analysis
  • 6.3 Company profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products and Services, and Recent Developments)
    • 6.3.1 Abbott Laboratories
    • 6.3.2 Boston Scientific Corporation
    • 6.3.3 Medtronic plc
    • 6.3.4 Terumo Corporation
    • 6.3.5 B. Braun SE
    • 6.3.6 Biosensors International Group Ltd
    • 6.3.7 SMT
    • 6.3.8 Lepu Medical Technology (Beijing) Co., Ltd
    • 6.3.9 Meril Life Sciences Pvt Ltd
    • 6.3.10 Cook Medical Inc
    • 6.3.11 Translumina GmbH
    • 6.3.12 MicroPort Scientific Corporation
    • 6.3.13 Cordis
    • 6.3.14 Alvimedica
    • 6.3.15 AMG International GmbH
    • 6.3.16 Balton Sp. z o.o.
    • 6.3.17 QualiMed Innovative Medizinprodukte GmbH
    • 6.3.18 Rontis AG
    • 6.3.19 Concept Medical Inc

7. Market Opportunities and Future Outlook

  • 7.1 White-Space and Unmet-Need Assessment
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Global Coronary Stent Market Report Scope

As per the report's scope, coronary stents are small elastic tubes used to treat narrowed and blocked coronary arteries in patients with coronary artery disease (CAD). The stent reduces the symptoms of chest pain (angina) and aids in treating a heart attack. These types of stents are also called heart stents or cardiac stents. They comprise metal mesh and are implanted in constricted coronary arteries during a technique known as percutaneous coronary intervention (PCI) or angioplasty. 

The Coronary Stent Market is Segmented by product type, biomaterial, end-users, and geography. By product type, the market is segmented into drug-eluting stents, bare metal coronary stents, and bioabsorbable stents. By biomaterial, the market is segmented into metallic biomaterial, polymeric biomaterial, and natural biomaterial. By end-users, the market is segmented into hospitals and ambulatory surgical centers. By geography, the market is segmented into North America, Europe, Asia-Pacific, Middle East and Africa, and South America. The report also covers the estimated market sizes and trends for 17 countries across major global regions. The report offers the value (USD) for the above segments.

By Product Type Drug-Eluting Stent (DES)
Bare-Metal Stent (BMS)
Bioabsorbable Vascular Scaffold (BVS)
Dual-Therapy Stent (DTS)
By Biomaterial Metallic
Polymeric
Natural / Bio-derived
By Mode of Delivery Balloon-Expandable Stent
Self-Expanding Stent
By End User Hospitals
Cardiac Catheterization Labs
Ambulatory Surgical Centers
By Geography North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa GCC
South Africa
Rest of Middle East and Africa
South America Brazil
Argentina
Rest of South America
By Product Type
Drug-Eluting Stent (DES)
Bare-Metal Stent (BMS)
Bioabsorbable Vascular Scaffold (BVS)
Dual-Therapy Stent (DTS)
By Biomaterial
Metallic
Polymeric
Natural / Bio-derived
By Mode of Delivery
Balloon-Expandable Stent
Self-Expanding Stent
By End User
Hospitals
Cardiac Catheterization Labs
Ambulatory Surgical Centers
By Geography
North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa GCC
South Africa
Rest of Middle East and Africa
South America Brazil
Argentina
Rest of South America
Need A Different Region or Segment?
Customize Now

Key Questions Answered in the Report

1. What is the current value of the coronary stents market?

The coronary stents market stands at USD 8.29 billion in 2025 and is set to reach USD 10.43 billion by 2030.

2. Which product segment dominates the coronary stents market?

Drug-eluting stents lead with 76.23% revenue share in 2024 due to proven safety and efficacy.

3. Why is Asia-Pacific the fastest-growing region?

Public procurement reforms, expanding healthcare infrastructure, and rising cardiovascular disease prevalence drive a 7.46% CAGR in Asia-Pacific.

4. How are AI technologies influencing stent procedures?

AI-guided imaging improves vessel assessment and sizing, cutting complication rates and optimizing resource use in cath labs.

5. What impact do government price caps have on manufacturers?

Price ceilings in markets such as India and China compress margins by up to 90%, pushing companies to localize production and streamline costs.

6. Are bioabsorbable vascular scaffolds gaining traction?

Yes, next-generation scaffolds show improved safety, leading to a projected 7.66% CAGR, although late thrombosis remains a watch point.

Page last updated on: June 21, 2025